NeuroPace (NPCE)
(Delayed Data from NSDQ)
$8.99 USD
+0.48 (5.64%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, NeuroPace, Inc. has a market cap of $279.11M, which represents its share price of $8.51 multiplied by its outstanding shares number of 32.80M. As a small-cap company, NPCE's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NPCE 8.99 +0.48(5.64%)
Will NPCE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NPCE
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
Other News for NPCE
NeuroPace (NPCE) Welcomes CMS Decision on RNS System Assignment
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with ...
NeuroPace 'commends' CMS for maintaining FY25 epilepsy reimbursement structure
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 | NPCE Stock News
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call